Acquired Company

Channel Therapeutics completed its merger with LNHC, Inc., resulting in Pelthos Therapeutics Inc., and the combined company began trading on the NYSE American under the ticker PTHS on July 2, 2025.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina. Show more

Location: 4020 Stirrup Creek Drive, Durham, NC, 27703, United States | Website: https://pelthos.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

74.14M

52 Wk Range

$9.00 - $54.29

Previous Close

$24.02

Open

$23.00

Volume

3,391

Day Range

$23.00 - $25.30

Enterprise Value

68.85M

Cash

14.2M

Avg Qtr Burn

-4.252M

Insider Ownership

54.35%

Institutional Own.

24.99%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Xeglyze/Abametapir (Metalloproteinase Inhibitor) Details Head Lice Infestation	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.